142 related articles for article (PubMed ID: 9213861)
1. [Comparative study of misoprostol and nifedipine in the treatment of Raynaud's phenomenon secondary to systemic diseases. Hemodynamic assessment with Doppler duplex].
Varela-Aguilar JM; Sánchez-Román J; Talegón Meléndez A; Castillo Palma MJ
Rev Clin Esp; 1997 Feb; 197(2):77-83. PubMed ID: 9213861
[TBL] [Abstract][Full Text] [Related]
2. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
[TBL] [Abstract][Full Text] [Related]
3. Acute effects of misoprostol on digital circulation in patients with Raynaud's phenomenon.
Wise RA; Wigley F
J Rheumatol; 1994 Jan; 21(1):80-3. PubMed ID: 8151594
[TBL] [Abstract][Full Text] [Related]
4. Cold stimulus fingertip lacticemy test--an effective method to monitor acute therapeutic intervention on primary Raynaud's phenomenon and systemic sclerosis.
Fontenelle SM; Kayser C; Pucinelli ML; Andrade LE
Rheumatology (Oxford); 2008 Jan; 47(1):80-3. PubMed ID: 18077495
[TBL] [Abstract][Full Text] [Related]
5. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
Fries R; Shariat K; von Wilmowsky H; Böhm M
Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
[TBL] [Abstract][Full Text] [Related]
6. The peripheral vascular effects of nifedipine in Raynaud's syndrome associated with scleroderma: a double blind crossover study.
Finch MB; Dawson J; Johnston GD
Clin Rheumatol; 1986 Dec; 5(4):493-8. PubMed ID: 3816096
[TBL] [Abstract][Full Text] [Related]
7. Nifedipine in Raynaud's phenomenon: relationship between immediate, short term and longterm effects.
Kallenberg CG; Wouda AA; Kuitert JJ; Tijssen J; Wesseling H
J Rheumatol; 1987 Apr; 14(2):284-90. PubMed ID: 3598997
[TBL] [Abstract][Full Text] [Related]
8. Vascular response of Raynaud's phenomenon to nifedipine or herbal medication (duhuo-tisheng tang with danggui-sini tang): a preliminary study.
Wu YJ; Luo SF; Yang SH; Chen JY; Yu KH; See LC
Chang Gung Med J; 2008; 31(5):492-502. PubMed ID: 19097597
[TBL] [Abstract][Full Text] [Related]
9. Nifedipine in the treatment of idiopathic Raynaud's syndrome.
Sarkozi J; Bookman AA; Mahon W; Ramsay C; Detsky AS; Keystone EC
J Rheumatol; 1986 Apr; 13(2):331-6. PubMed ID: 3723496
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis.
Gardinali M; Pozzi MR; Bernareggi M; Montani N; Allevi E; Catena L; Cugno M; Bottasso B; Stabilini R
J Rheumatol; 2001 Apr; 28(4):786-94. PubMed ID: 11327251
[TBL] [Abstract][Full Text] [Related]
11. Nifedipine and Raynaud's phenomenon associated with connective tissue diseases.
Kahan A; Weber S; Amor B; Menkes CJ; Hodara M; Degeorges M
Int Angiol; 1985; 4(2):221-3. PubMed ID: 3831143
[TBL] [Abstract][Full Text] [Related]
12. Slow release nifedipine in the treatment of Raynaud's phenomenon.
Costantini A; Martelli E; Bavera P; Agus GB
Int Angiol; 1987; 6(4):359-63. PubMed ID: 3330116
[TBL] [Abstract][Full Text] [Related]
13. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.
Dziadzio M; Denton CP; Smith R; Howell K; Blann A; Bowers E; Black CM
Arthritis Rheum; 1999 Dec; 42(12):2646-55. PubMed ID: 10616013
[TBL] [Abstract][Full Text] [Related]
14. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
15. [Controlled study of nifedipine in the treatment of Raynaud's phenomenon].
Kahan A; Weber S; Amor B; Saporta L; Hodara M; Degeorges M
Rev Rhum Mal Osteoartic; 1982 Apr; 49(5):337-43. PubMed ID: 6285445
[TBL] [Abstract][Full Text] [Related]
16. Acute effects of nifedipine on digital blood flow in human subjects with Raynaud's phenomenon: a double blind placebo controlled trial.
Wise RA; Malamet R; Wigley FM
J Rheumatol; 1987 Apr; 14(2):278-83. PubMed ID: 3298649
[TBL] [Abstract][Full Text] [Related]
17. [Action of nifedipine on the post-ischemic cold hyperemia reaction in Raynaud's phenomenon].
Vayssairat M; Blaison N; Baudot N; Evenou P; Gilard M; Mathieu JF
J Mal Vasc; 1989; 14(4):299-302. PubMed ID: 2584886
[TBL] [Abstract][Full Text] [Related]
18. Responses to nifedipine by patients with Raynaud's disease and Raynaud's phenomenon secondary to another disease.
Riccio A; Del Puente A; Farinaro C; Scarpa R; Oriente P; Rocco P; Gioia M
Clin Ther; 1987; 9(2):232-7. PubMed ID: 3568066
[TBL] [Abstract][Full Text] [Related]
19. Quantitative study of the effects of Ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled investigation and an additional long term open trial.
van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
Microcirc Endothelium Lymphatics; 1985; 2(6):657-85. PubMed ID: 2942753
[TBL] [Abstract][Full Text] [Related]
20. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon.
Bartolone S; Trifiletti A; De Nuzzo G; Scamardi R; Larosa D; Sottilotta G; Raffa A; Barbera N
Minerva Cardioangiol; 1999 May; 47(5):137-43. PubMed ID: 10479851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
